Hobbs Group Advisors’s Oncolytics Biotech ONCY Stock Holding History

Hobbs Group Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$142	Buy	+105	New	+$164	﹤0.01%	535

Other funds holding ONCY

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hobbs Group Advisors's ONCY Position: Q4 2023 in Review

Hobbs Group Advisors opened a new position in Oncolytics Biotech (ONCY) in Q4 2023: 105 shares worth $142. The stake represents ﹤0.01% of the portfolio and ranks #535 among its holdings.

44 funds tracked by Wall St. Rank hold ONCY as of Q4 2023.

Hobbs Group Advisors held 105 shares of Oncolytics Biotech worth $142 as of Q4 2023.
Oncolytics Biotech was a new Hobbs Group Advisors position in Q4 2023.
Oncolytics Biotech made up ﹤0.01% of Hobbs Group Advisors's portfolio in Q4 2023, its #535 holding.
44 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2023.

Based on Hobbs Group Advisors's 13F filing for Q4 2023, filed 16 Feb 2024.